The administration schedule of cyclin-dependent kinase inhibitor gene therapy and etoposide chemotherapy is a major determinant of cytotoxicity.

International journal of oncology

Volumn 15, Issue 2, 1999, Pages 209-216

  Prabhu, N S ^a   Somasundaram, K ^a   Tian, H ^a   Enders, G H ^a   Satyamoorthy, K ^a   Herlyn, M ^a   El Deiry, W S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENZYME INHIBITOR; ETOPOSIDE;

ARTICLE; BONE TUMOR; CELL CYCLE; CELL SURVIVAL; DNA DAMAGE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; METHODOLOGY; OSTEOSARCOMA; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE NEOPLASMS; CELL CYCLE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; ETOPOSIDE; GENE THERAPY; GENES, P16; HUMANS; OSTEOSARCOMA;

MLCS; MLOWN;

EID: 0033175624     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.15.2.209     Document Type: Article

References (0)